Lubetzki C, Thuillier Y, Galli A, Lyon-Caen O, Lhermitte F, Zalc B
Laboratoire de neurobiologie cellulaire, moléculaire, et clinique, INSERM U-134, Hôpital de la Salpêtrière, Paris, France.
Ann Neurol. 1989 Sep;26(3):407-9. doi: 10.1002/ana.410260319.
Eight patients with multiple sclerosis were followed for several months to determine if serum levels of galactosylceramide, a major lipid component of myelin, correlate with the clinical evolution of the disease. In the patients with the chronic progressive form of multiple sclerosis, galactosylceramide remained undetectable. In the patients with relapsing-remitting multiple sclerosis, there was a good correlation between the elevation of serum galactosylceramide levels and clinical relapses. This serum assay should prove of value in the follow-up of patients with multiple sclerosis.
对8名多发性硬化症患者进行了数月的跟踪，以确定髓鞘的主要脂质成分半乳糖神经酰胺的血清水平是否与该疾病的临床进展相关。在患有慢性进行性多发性硬化症的患者中，未检测到半乳糖神经酰胺。在复发缓解型多发性硬化症患者中，血清半乳糖神经酰胺水平的升高与临床复发之间存在良好的相关性。这种血清检测方法在多发性硬化症患者的随访中应具有价值。
